XM does not provide services to residents of the United States of America.
E
E

EMS

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Swiss EMS Chemie H1 sales drop 8.1%, cuts 2024 sales guidance

UPDATE 1-Swiss EMS Chemie H1 sales drop 8.1%, cuts 2024 sales guidance Adds analyst comments in paragraphs 3, 8, 10, share move in paragraph 2 July 12 (Reuters) - Swiss nylon manufacturer EMS Chemie EMSN.S cut its 2024 sales guidance on Friday after reporting weaker-than-expected first-half sales, citing currency effects as the Swiss franc strengthened.
E
G
K

EMS Chemie slumps on H1 sales miss

BUZZ-EMS Chemie slumps on H1 sales miss ** Shares of Swiss nylon manufacturer EMS Chemie EMSN.S fall around 7% to more than two-month lows after its H1 sales missed expectations ** Net sales in the first half of the year declined 8.1% to 1.09 billion Swiss francs ($1.22 billion) ** "1H24 sales were weak and did not meet expectations," Vontobel says
E

Swiss EMS Chemie cuts 2024 sales guidance on currency effects

Swiss EMS Chemie cuts 2024 sales guidance on currency effects July 12 (Reuters) - Swiss nylon manufacturer EMS Chemie EMSN.S cut its 2024 sales guidance on Friday, citing currency effects as the Swiss franc strengthened. The company said it expects its 2024 net sales to fall slightly, after previously forecasting net sales in line with the 2023 figure of 2.19 billion Swiss francs ($2.44 billion).
C
E
G

Swiss stocks - Factors to watch on July 12

Swiss stocks - Factors to watch on July 12 July 12 - Here are some of the main factors that may affect Swiss stocks on Friday: EMS CHEMIE HOLDING AG EMSN.S Reports H1 EBITDA up at 318 million Swiss francs. PARTNERS GROUP HOLDING AG PGHN.S Reports 11 billion dollars in H1 client demand, reconfirms FY fundraising guidance. ANALYSTS' VIEWS DOCMORRIS DOCM.S - HSBC CUTS TARGET PRICE TO CHF 75 FROM CHF 115 ECONOMY No major Swiss economic data scheduled.
E

EMS Chemie H1 EBITDA up at CHF 318 Million

BRIEF-EMS Chemie H1 EBITDA up at CHF 318 Million July 12 (Reuters) - EMS Chemie EMSN.S : H1 NET SALES AMOUNTING TO CHF 1,087 MILLION (1,183) H1 NET OPERATING INCOME OF CHF 291 MILLION (280) H1 EBITDA of CHF 318 million (305) FOR 2024, EMS EXPECTS NET SALES SLIGHTLY BELOW PREVIOUS YEAR DUE TO CURRENCY EFFECTS AND CONTINUES TO EXPECT NET OPERATING IN
E

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.